Top Markets
Coin of the day
Egetis Therapeutics AB (publ) Egetis Therapeutics AB (publ)

Egetis Therapeutics AB (publ)

EGTX
Classifica tra le azioni #14604
Egetis Therapeutics AB (publ) is a pharmaceutical enterprise committed to... Egetis Therapeutics AB (publ) is a pharmaceutical enterprise committed to progressing drug development, primarily focusing on late-stage projects. The company's core mission involves addressing significant unmet medical needs within the orphan drug sector, concentrating on severe and rare or niche diseases. Its current therapeutic pipeline includes two key drugs undergoing Phase IIb/III clinical trials: Aladote, which is designed to mitigate the risk of acute liver damage associated with acetaminophen/paracetamol poisoning, and Emcitate, intended for the management of MCT8 deficiency, a rare congenital disorder impacting thyroid hormone signaling. Established in 2006, Egetis Therapeutics AB (publ) is headquartered in Stockholm, Sweden, and was previously known as PledPharma AB (publ) until its name change in December 2020.
Prezzo delle azioni
$0.86785876
Capitalizzazione di mercato
$403.51M
Variazione (1 giorno)
-1.02%
Variazione (1 anno)
56.42%
Paese
SE
Scambia Egetis Therapeutics AB (publ) (EGTX)

Categoria

Rapporto P/B per Egetis Therapeutics AB (publ) (EGTX)
Rapporto P/B al 2026 TTM: 0
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Egetis Therapeutics AB (publ), il rapporto P/B attuale (TTM) è 0. Alla fine del 2026, era pari a 0.
Storico del rapporto P/B per Egetis Therapeutics AB (publ) da 2026 a 2026
Rapporto P/B alla fine di ogni anno
Anno Rapporto P/B Cambia
Non abbastanza dati per le date fornite.
Rapporto P/B per aziende simili o concorrenti
Azienda Rapporto P/B Differenza del rapporto P/B Il paese
6.828 -
US
7.5116 -
NL
3.9942 -
AU
8.2199 -
US
- -
CH